Mavacamten · Camzyos

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Hypertrophic Cardiomyopathy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Heart Failure · Phase 2 · investigational in the US

Also approved (3)
JP
  • Treatment of symptomatic obstructive hypertrophic cardiomyopathy
Product first approved 2025PMDA
EU
  • Treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults (Camzyos; MAH Bristol-Myers Squibb Pharma EEIG)
Product first approved 2023EMA
CA
  • CAMZYOS (mavacamten capsules) is indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) Class II-III in adult patients.
Product first approved 2022Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (7)
Hypertrophic Cardiomyopathy
NCT07940777 · Bristol-Myers Squibb
2026-12-29 – 2032-07-19 · Non-obstructive Hypertrophic Cardiomyopathy
What this study did
NCT05414175 · Bristol-Myers Squibb
2022-08-19 – 2025-12-11 · Cardiomyopathy, Hypertrophic Obstructive
What this study did
NCT05174416 · LianBio LLC
2022-01-04 – 2024-07-22 · Obstructive Hypertrophic Cardiomyopathy
What this study did
Phase 2/3 (1)
Hypertrophic Cardiomyopathy
NCT03723655 · Bristol-Myers Squibb
2018-09-27 – 2026-01-16 · Hypertrophic Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy, Non-obstructive Hypertrophic Cardiomyopathy
What this study did
Phase 2 (4)
Heart Failure
Hypertrophic Cardiomyopathy
NCT03496168 · Bristol-Myers Squibb
2018-04-26 – 2023-11-09 · Hypertrophic Cardiomyopathy
What this study did
NCT03442764 · MyoKardia, Inc.
2018-03-30 – 2020-01-07 · Non-obstructive Hypertrophic Cardiomyopathy
What this study did
NCT02842242 · MyoKardia, Inc.
2016-08 – 2017-11 · Cardiomyopathy, Hypertrophic Obstructive, Left Ventricular Outflow Tract Obstruction
What this study did
Phase 1 (9)
Hypertrophic Cardiomyopathy
NCT05135871 · LianBio LLC
2021-10-31 – 2022-02-28 · Hypertrophic Cardiomyopathy
What this study did
NCT02329184 · MyoKardia, Inc.
2014-12 – 2016-04 · Hypertrophic Cardiomyopathy
What this study did
Other / comorbidity
NCT05719805 · Bristol-Myers Squibb
2023-02-20 – 2023-07-25 · Healthy Participants
What this study did
NCT05658146 · Bristol-Myers Squibb
2023-01-06 – 2023-07-05 · Healthy Participants
What this study did
NCT05320094 · Bristol-Myers Squibb
2022-04-15 – 2022-09-11 · Healthy Participants
What this study did
NCT05362045 · Bristol-Myers Squibb
2022-05-16 – 2022-08-19 · Healthy Participants
What this study did
NCT02480296 · MyoKardia, Inc.
2015-08 – 2016-10 · Healthy
What this study did
NCT02356289 · MyoKardia, Inc.
2015-01 – 2015-07 · Healthy
What this study did
Phase 4 (4)
Hypertrophic Cardiomyopathy
NCT07807384 · Second Affiliated Hospital of Nanchang University
2026-11 – 2029-09 · Obstructive Hypertrophic Cardiomyopathy (oHCM)
What this study did
NCT07004972 · Bristol-Myers Squibb
2025-09-04 – 2027-12-13 · Symptomatic Obstructive Hypertrophic Cardiomyopathy
What this study did
NCT06112743 · Bristol-Myers Squibb
2024-01-24 – 2027-06-10 · Cardiomyopathy, Hypertrophic
What this study did
NCT07103655 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2026-03-01 – 2027-01-01 · Hypertrophic Cardiomyopathy (HCM)
What this study did
Early phase / not applicable (4)
Hypertrophic Cardiomyopathy
NCT07815301 · First Affiliated Hospital of Wenzhou Medical University
2026-12 – 2028-12 · Obstructive Hypertrophic Cardiomyopathy (oHCM)
What this study did
NCT07120776 · University of Manchester
2026-03-26 – 2028-10 · Hypertrophic Obstructive Cardiomyopathy \(HOCM\), Left Ventricular Outflow Tract Obstruction, Myocardial Ischaemia
What this study did
NCT07077005 · Technical University of Munich
2025-11-01 – 2027-01-31 · Cardiomyopathy, Hypertrophic
What this study did
NCT06947590 · Xu Liu
2025-04-20 – 2026-02-01 · HCM - Hypertrophic Cardiomyopathy, Mavacamten
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Early phase / not applicable (1)
Hypertrophic Cardiomyopathy
NCT06856265 · Shanghai Chest Hospital
2025-02-26 – 2025-12-01 · Obstructive Hypertrophic Cardiomyopathy, Mavacamten, Radiofrequency Ablation
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Hypertrophic Cardiomyopathy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Mavacamten (Camzyos): this drugApprovedSmall moleculeCardiac myosin (inhibitor)Partial signal
NCT04349072: Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16 (Week 16): Mavacamten 10 Participants | Placebo to Mavacamten 43 Participants
Aficamten (Myqorzo)ApprovedSmall moleculeCardiac myosin (inhibitor)Reliable signal
NCT05767346: Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET) (Baseline to Week 24): Aficamten 1.07 mL/kg/min (Standard Deviation 2.767) | Metoprolol -1.24 mL/kg/min (Standard Deviation 2.186)
NCT05186818: Change From Baseline in pVO2 at Week 24 (Baseline to Week 24): Aficamten up to 20 mg 1.76 mL/kg/min (Standard Error 0.25) | Placebo to Match Aficamten 0.02 mL/kg/min (Standard Error 0.25)
Propranolol (Inderal LA)ApprovedSmall moleculeBeta-1/beta-2 adrenergic receptorsnot yet gradedNo reviewed efficacy summary in this indication
HRS-1893Phase 3UndisclosedCardiac myosin (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
Sotagliflozin (Inpefa)Phase 3Small moleculeSGLT1/2 (dual)not yet gradedNo reviewed efficacy summary in this indication
Ninerafaxstat (IMB-101)Phase 2Small moleculeCardiac fatty-acid oxidationnot yet gradedNo reviewed efficacy summary in this indication
Ulacamten
Phase 2(overall)
Small moleculeCardiac myosin (inhibitor)
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Camzyos (Mavacamten) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Phase 4Hypertrophic CardiomyopathyActive not recruiting
Est. primary completion 2027-12-13 · NCT07004972 · CT.gov ↗
What to watch
2028 (2)
October 2028 (1)
Early phase / not applicableHypertrophic CardiomyopathyRecruiting
Est. primary completion 2028-10 · NCT07120776 · CT.gov ↗
What to watch
December 2028 (1)
Early phase / not applicableHypertrophic CardiomyopathyNot yet recruiting
Est. primary completion 2028-12 · NCT07815301 · CT.gov ↗
What to watch
2029 (2)
July 2029 (1)
Phase 3Hypertrophic CardiomyopathyNot yet recruiting
Est. primary completion 2029-07-21 · NCT07940777 · CT.gov ↗
What to watch
September 2029 (1)
Phase 4Hypertrophic CardiomyopathyNot yet recruiting
Est. primary completion 2029-09 · NCT07807384 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

14 April 2025Topline resultODYSSEY-HCM (NCT05582395) Phase 3 missed its primary endpoints
Bristol Myers Squibb · Source ↗